KR101799005B1 - 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 - Google Patents
히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR101799005B1 KR101799005B1 KR1020160095326A KR20160095326A KR101799005B1 KR 101799005 B1 KR101799005 B1 KR 101799005B1 KR 1020160095326 A KR1020160095326 A KR 1020160095326A KR 20160095326 A KR20160095326 A KR 20160095326A KR 101799005 B1 KR101799005 B1 KR 101799005B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- alkyl
- synthesis
- methyl
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@](C(C)=*)N=IIC(C)=*C Chemical compound C[C@](C(C)=*)N=IIC(C)=*C 0.000 description 25
- ZTHGQBAUPMNVKT-UHFFFAOYSA-N COC(c1ccc(CN(c2cccc(Cl)c2)S(N(CC2)CCN2C2CCC2)(=O)=O)nc1)=O Chemical compound COC(c1ccc(CN(c2cccc(Cl)c2)S(N(CC2)CCN2C2CCC2)(=O)=O)nc1)=O ZTHGQBAUPMNVKT-UHFFFAOYSA-N 0.000 description 2
- QRDQCQSRGOUHRK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1S(N(Cc(nc1)ccc1C(OC)=O)c(cc1C)ccc1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1S(N(Cc(nc1)ccc1C(OC)=O)c(cc1C)ccc1F)(=O)=O)=O QRDQCQSRGOUHRK-UHFFFAOYSA-N 0.000 description 1
- VRPLJBRKXGRONA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1S(Nc(cc1C)ccc1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1S(Nc(cc1C)ccc1F)(=O)=O)=O VRPLJBRKXGRONA-UHFFFAOYSA-N 0.000 description 1
- VFAZYPAOYUXHLT-UHFFFAOYSA-N CC(C)(CN(C)CC1)CN1S(NI)(=O)=O Chemical compound CC(C)(CN(C)CC1)CN1S(NI)(=O)=O VFAZYPAOYUXHLT-UHFFFAOYSA-N 0.000 description 1
- CFBZLUWOASRBQE-UHFFFAOYSA-N CC(C)(CN(CC1)S(NI)(=O)=O)C[N]1(C)C1CC1 Chemical compound CC(C)(CN(CC1)S(NI)(=O)=O)C[N]1(C)C1CC1 CFBZLUWOASRBQE-UHFFFAOYSA-N 0.000 description 1
- YIMYMZMBPHDTOB-UHFFFAOYSA-N CC(C)C(N(CC1)CCN1S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1ccccc1)(=O)=O)=O Chemical compound CC(C)C(N(CC1)CCN1S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1ccccc1)(=O)=O)=O YIMYMZMBPHDTOB-UHFFFAOYSA-N 0.000 description 1
- FFIHKZARVLWSBF-UHFFFAOYSA-N CC(C)N(CC1)CCN1S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O Chemical compound CC(C)N(CC1)CCN1S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O FFIHKZARVLWSBF-UHFFFAOYSA-N 0.000 description 1
- XLCOBTYRMPFPIJ-UHFFFAOYSA-N CC(N(CC1)CCN1S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1cccc(F)c1)(=O)=O)=O Chemical compound CC(N(CC1)CCN1S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1cccc(F)c1)(=O)=O)=O XLCOBTYRMPFPIJ-UHFFFAOYSA-N 0.000 description 1
- XMVNXQQETDBGFF-UHFFFAOYSA-N CC(N1CCN(CCN(C)S(N(Cc(cc2)ccc2C(OC)=O)c2ccccc2)(=O)=O)CC1)=O Chemical compound CC(N1CCN(CCN(C)S(N(Cc(cc2)ccc2C(OC)=O)c2ccccc2)(=O)=O)CC1)=O XMVNXQQETDBGFF-UHFFFAOYSA-N 0.000 description 1
- UXYQAZQKDRYBBE-UHFFFAOYSA-N CC/C=B\Cc(nc1)ccc1C(OC)=O Chemical compound CC/C=B\Cc(nc1)ccc1C(OC)=O UXYQAZQKDRYBBE-UHFFFAOYSA-N 0.000 description 1
- HBPXHBOXPPFFLL-HDICACEKSA-N CCN([C@H](C)C1)[C@@H](C)CN1S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O Chemical compound CCN([C@H](C)C1)[C@@H](C)CN1S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O HBPXHBOXPPFFLL-HDICACEKSA-N 0.000 description 1
- SBXSUPAFTJURQE-UHFFFAOYSA-N CN(CCN1CCN(C)CC1)S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O Chemical compound CN(CCN1CCN(C)CC1)S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O SBXSUPAFTJURQE-UHFFFAOYSA-N 0.000 description 1
- YRQCLNOYFTTWJY-UHFFFAOYSA-N CN(CCN1CCNCC1)S(N(Cc(cc1)ccc1C(OC)=O)c1ccccc1)(=O)=O Chemical compound CN(CCN1CCNCC1)S(N(Cc(cc1)ccc1C(OC)=O)c1ccccc1)(=O)=O YRQCLNOYFTTWJY-UHFFFAOYSA-N 0.000 description 1
- DIEYHLYBYAEFFZ-UHFFFAOYSA-N COC(Cc1ccc(CN(c2ccccc2)S(N2CCNCC2)(=O)=O)c(F)c1)=O Chemical compound COC(Cc1ccc(CN(c2ccccc2)S(N2CCNCC2)(=O)=O)c(F)c1)=O DIEYHLYBYAEFFZ-UHFFFAOYSA-N 0.000 description 1
- RNOFEBYIDNPCCX-UHFFFAOYSA-N COC(c1ccc(CN(c2cccc(Cl)c2)S(N2CCNCC2)(=O)=O)nc1)=O Chemical compound COC(c1ccc(CN(c2cccc(Cl)c2)S(N2CCNCC2)(=O)=O)nc1)=O RNOFEBYIDNPCCX-UHFFFAOYSA-N 0.000 description 1
- RACOLDKCUZXRSP-UHFFFAOYSA-N COC(c1ccc(CN(c2ccccc2)S(N(CC2)CCN2C2COC2)(=O)=O)c(F)c1)=O Chemical compound COC(c1ccc(CN(c2ccccc2)S(N(CC2)CCN2C2COC2)(=O)=O)c(F)c1)=O RACOLDKCUZXRSP-UHFFFAOYSA-N 0.000 description 1
- VTFFRINHSSWGGS-LBPRGKRZSA-N C[C@@H](CN(CC1)S(Nc2cccc(Cl)c2)(=O)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CN(CC1)S(Nc2cccc(Cl)c2)(=O)=O)N1C(OC(C)(C)C)=O VTFFRINHSSWGGS-LBPRGKRZSA-N 0.000 description 1
- JSYLJTSBBPHYGB-IYBDPMFKSA-N C[C@H](C1)N(C)[C@@H](C)CN1S(N(Cc(cc1)ccc1C(NN)=O)c1cccnc1)(=O)=O Chemical compound C[C@H](C1)N(C)[C@@H](C)CN1S(N(Cc(cc1)ccc1C(NN)=O)c1cccnc1)(=O)=O JSYLJTSBBPHYGB-IYBDPMFKSA-N 0.000 description 1
- NRKCUFCCWXJAAY-IYBDPMFKSA-N C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(NN)=O)c2cnccc2)(=O)=O)N1C(C)=O Chemical compound C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(NN)=O)c2cnccc2)(=O)=O)N1C(C)=O NRKCUFCCWXJAAY-IYBDPMFKSA-N 0.000 description 1
- JXUODWWRSLAQRB-BGYRXZFFSA-N C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(OC)=O)c2ccccc2)(=O)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(OC)=O)c2ccccc2)(=O)=O)N1C(OC(C)(C)C)=O JXUODWWRSLAQRB-BGYRXZFFSA-N 0.000 description 1
- RSCSFQXFGJJMJQ-CALCHBBNSA-N C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(OC)=O)c2cccnc2)(=O)=O)N1C(C)=O Chemical compound C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(OC)=O)c2cccnc2)(=O)=O)N1C(C)=O RSCSFQXFGJJMJQ-CALCHBBNSA-N 0.000 description 1
- JEKVYWBEVCXPET-OKILXGFUSA-N C[C@H](CN(C[C@@H]1C)S(Nc2ccccc2)(=O)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(C[C@@H]1C)S(Nc2ccccc2)(=O)=O)N1C(OC(C)(C)C)=O JEKVYWBEVCXPET-OKILXGFUSA-N 0.000 description 1
- YKUQSOROGCXWAT-BETUJISGSA-N C[C@H](CN(C[C@@H]1C)S(Nc2cccnc2)(=O)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(C[C@@H]1C)S(Nc2cccnc2)(=O)=O)N1C(OC(C)(C)C)=O YKUQSOROGCXWAT-BETUJISGSA-N 0.000 description 1
- KRMGKHXKGRBICV-UHFFFAOYSA-N Cc1cc(N(Cc(cc2)ccc2C(OC)=O)S(N(CC2)CCN2C2CCC2)(=O)=O)ccc1F Chemical compound Cc1cc(N(Cc(cc2)ccc2C(OC)=O)S(N(CC2)CCN2C2CCC2)(=O)=O)ccc1F KRMGKHXKGRBICV-UHFFFAOYSA-N 0.000 description 1
- ZONMQRYMGQTIBR-UHFFFAOYSA-N Cc1cc(N(Cc(cc2)ccc2C(OC)=O)S(N2CCNCC2)(=O)=O)ccc1F Chemical compound Cc1cc(N(Cc(cc2)ccc2C(OC)=O)S(N2CCNCC2)(=O)=O)ccc1F ZONMQRYMGQTIBR-UHFFFAOYSA-N 0.000 description 1
- MVKSCNPSFAUQTD-UHFFFAOYSA-N NNC(c1ccc(CN(c2cccc(Cl)c2)S(N(CC2)CCN2C2CCC2)(=O)=O)nc1)=O Chemical compound NNC(c1ccc(CN(c2cccc(Cl)c2)S(N(CC2)CCN2C2CCC2)(=O)=O)nc1)=O MVKSCNPSFAUQTD-UHFFFAOYSA-N 0.000 description 1
- DXQHZDLZGXUOHY-UHFFFAOYSA-N O=S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1ccccc1)(N1CCNCC1)=O Chemical compound O=S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1ccccc1)(N1CCNCC1)=O DXQHZDLZGXUOHY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150106177 | 2015-07-27 | ||
| KR1020150106177 | 2015-07-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170013186A KR20170013186A (ko) | 2017-02-06 |
| KR101799005B1 true KR101799005B1 (ko) | 2017-11-17 |
Family
ID=57885712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160095326A Active KR101799005B1 (ko) | 2015-07-27 | 2016-07-27 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10464911B2 (OSRAM) |
| EP (1) | EP3328844B1 (OSRAM) |
| JP (1) | JP6538266B2 (OSRAM) |
| KR (1) | KR101799005B1 (OSRAM) |
| CN (1) | CN107980040B (OSRAM) |
| AU (1) | AU2016299486B2 (OSRAM) |
| BR (1) | BR112017027798B1 (OSRAM) |
| CA (1) | CA2987570C (OSRAM) |
| DK (1) | DK3328844T3 (OSRAM) |
| ES (1) | ES2774510T3 (OSRAM) |
| HR (1) | HRP20200280T1 (OSRAM) |
| HU (1) | HUE048534T2 (OSRAM) |
| MX (1) | MX376585B (OSRAM) |
| MY (1) | MY194018A (OSRAM) |
| NZ (1) | NZ736432A (OSRAM) |
| PH (1) | PH12017501939A1 (OSRAM) |
| PL (1) | PL3328844T3 (OSRAM) |
| PT (1) | PT3328844T (OSRAM) |
| RU (1) | RU2695227C9 (OSRAM) |
| TW (1) | TWI694074B (OSRAM) |
| WO (1) | WO2017018805A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016258188B2 (en) | 2015-05-07 | 2021-08-26 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| KR20180002730A (ko) | 2015-05-07 | 2018-01-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법 |
| NZ739026A (en) | 2015-07-27 | 2019-03-29 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| KR101799005B1 (ko) | 2015-07-27 | 2017-11-17 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
| BR112018002304B1 (pt) | 2015-08-04 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| WO2017065473A1 (en) | 2015-10-12 | 2017-04-20 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| TW201910328A (zh) * | 2017-07-31 | 2019-03-16 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| KR102059027B1 (ko) * | 2018-01-12 | 2019-12-24 | 주식회사 비엔에이치리서치 | Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물 |
| KR102316234B1 (ko) * | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| US12084436B2 (en) | 2019-01-30 | 2024-09-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| BR112021020682A2 (pt) | 2019-04-17 | 2021-12-07 | Fund Kertor | Derivados de 1,3,4-oxadiazol como inibidores de histona deacetilase |
| MX2021014315A (es) | 2019-05-31 | 2022-01-04 | Chong Kun Dang Pharmaceutical Corp | Compuestos derivados de 1,3,4-oxadiazol homoftalimida como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. |
| CA3144985A1 (en) | 2019-06-27 | 2020-12-30 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Hdac6-activated macrophages, compositions, and uses thereof |
| AR120040A1 (es) | 2019-09-27 | 2022-01-26 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
| CA3165424A1 (en) | 2019-12-20 | 2021-06-24 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| KR102537616B1 (ko) * | 2020-02-25 | 2023-05-26 | 주식회사 종근당 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| MX2023000625A (es) * | 2020-07-14 | 2023-02-22 | Chong Kun Dang Pharmaceutical Corp | Nuevos compuestos como inhibidor de histona desacetilasa 6, y composicion farmaceutica que los comprende. |
| JP2023537052A (ja) | 2020-08-07 | 2023-08-30 | イタルファルマコ ソシエタ ペル アチオニ | 新規オキサジアゾール系の選択的ｈｄａｃ６阻害剤 |
| CA3211625A1 (en) * | 2021-04-08 | 2022-10-13 | Chang Sik Lee | 1,3,4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| TW202308619A (zh) | 2021-05-04 | 2023-03-01 | 美商特納亞治療股份有限公司 | 用於治療代謝疾病和hfpef的hdac6抑制劑 |
| TW202412772A (zh) | 2022-07-19 | 2024-04-01 | 義大利商義大利藥品股份有限公司 | 作為選擇性組蛋白去乙醯酶６抑制劑之１，３，４－㗁二唑衍生物 |
| EP4568949A1 (en) | 2022-08-08 | 2025-06-18 | Italfarmaco SpA | Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors |
| KR20240035172A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
| IL319658A (en) * | 2022-10-14 | 2025-05-01 | Chong Kun Dang Pharmaceutical Corp | Sulfoximine compounds as histone deacetylase 6 inhibitors, and a pharmaceutical composition comprising the same |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070293530A1 (en) | 2006-06-14 | 2007-12-20 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| WO2010123933A1 (en) | 2009-04-20 | 2010-10-28 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| WO2012013716A1 (en) | 2010-07-29 | 2012-02-02 | Novartis Ag | Bicyclic acetyl-coa carboxylase inhibitors |
| US20120289495A1 (en) | 2010-01-13 | 2012-11-15 | Tempero Pharmaceuticals Inc. | Compounds and methods |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0276432A3 (de) | 1986-12-12 | 1988-10-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
| KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| CA2462601A1 (en) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| IL162498A0 (en) | 2001-12-20 | 2005-11-20 | Bristol Myers Squibb Co | (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same |
| AU2006270322A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP2388263A1 (en) | 2005-08-04 | 2011-11-23 | Sirtris Pharmaceuticals, Inc. | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators |
| WO2007032445A1 (ja) | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
| NZ571271A (en) | 2006-03-23 | 2011-10-28 | Biota Europe Ltd | The use of benzamide or pyridinamide derivatives as antibacterial agents |
| EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| RU2482877C2 (ru) | 2006-12-11 | 2013-05-27 | Дженентек, Инк. | Композиции и способы для лечения опухоли |
| WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
| KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
| JP2011502133A (ja) | 2007-11-02 | 2011-01-20 | メシルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| SG185925A1 (en) | 2007-11-02 | 2012-12-28 | Momenta Pharmaceuticals Inc | Non-anticoagulant polysaccharide compositions |
| CA2731730C (en) * | 2008-07-23 | 2017-06-13 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
| JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
| WO2011011186A2 (en) | 2009-07-22 | 2011-01-27 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| LT2526093T (lt) | 2010-01-22 | 2016-10-10 | Acetylon Pharmaceuticals, Inc. | Grįžtamieji amido junginiai kaip baltymo deacetilazės inhibitoriai ir jų panaudojimo būdai |
| EP2539327A1 (en) | 2010-02-25 | 2013-01-02 | Piramal Enterprises Limited | Oxadiazole compounds, their preparation and use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| CA2798763A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| RU2601550C2 (ru) | 2010-12-09 | 2016-11-10 | Вокхардт Лимитед | Кетолидные соединения |
| KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
| EP2729454B1 (en) | 2011-07-08 | 2015-09-16 | Novartis AG | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| JP6169076B2 (ja) | 2011-07-20 | 2017-07-26 | ザ ジェネラル ホスピタル コーポレイション | 骨疾患の処置のためのヒストン脱アセチル化酵素６選択的阻害剤 |
| WO2013041407A1 (en) | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| US9499479B2 (en) | 2011-10-03 | 2016-11-22 | The Trustees Of Columbia University In The City Of New York | Molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| BR112014012815A8 (pt) | 2011-11-28 | 2017-06-20 | Novartis Ag | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença |
| US9345905B2 (en) | 2011-11-29 | 2016-05-24 | Nanjing Allgen Pharma Co. Ltd. | Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents |
| CA2866707A1 (en) | 2012-03-07 | 2013-09-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
| CU24345B1 (es) | 2013-09-06 | 2018-05-08 | Aurigene Discovery Tech Ltd | Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores |
| DK3080125T3 (en) * | 2013-12-12 | 2019-01-07 | Chong Kun Dang Pharmaceutical Corp | PRESENT UNKNOWN AZA DERIVATIVE DERIVATIVES AS SELECTIVE HISTONDEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THESE |
| CN104744446B (zh) | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| ES2713700T3 (es) * | 2014-11-24 | 2019-05-23 | Medifron Dbt Inc | Derivados de carboxamida y urea a base de oxazol y tiazol sustituidos como ligandos del receptor de vainilloide II |
| CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
| NZ739026A (en) | 2015-07-27 | 2019-03-29 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| KR101799005B1 (ko) | 2015-07-27 | 2017-11-17 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
| BR112018002304B1 (pt) | 2015-08-04 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| WO2017065473A1 (en) | 2015-10-12 | 2017-04-20 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
-
2016
- 2016-07-27 KR KR1020160095326A patent/KR101799005B1/ko active Active
- 2016-07-27 RU RU2018106904A patent/RU2695227C9/ru active
- 2016-07-27 CA CA2987570A patent/CA2987570C/en active Active
- 2016-07-27 MX MX2017017090A patent/MX376585B/es active IP Right Grant
- 2016-07-27 DK DK16830838.5T patent/DK3328844T3/da active
- 2016-07-27 BR BR112017027798-0A patent/BR112017027798B1/pt active IP Right Grant
- 2016-07-27 EP EP16830838.5A patent/EP3328844B1/en active Active
- 2016-07-27 HU HUE16830838A patent/HUE048534T2/hu unknown
- 2016-07-27 NZ NZ736432A patent/NZ736432A/en unknown
- 2016-07-27 PT PT168308385T patent/PT3328844T/pt unknown
- 2016-07-27 US US15/747,850 patent/US10464911B2/en active Active
- 2016-07-27 MY MYPI2017703935A patent/MY194018A/en unknown
- 2016-07-27 WO PCT/KR2016/008218 patent/WO2017018805A1/en not_active Ceased
- 2016-07-27 TW TW105123853A patent/TWI694074B/zh active
- 2016-07-27 PL PL16830838T patent/PL3328844T3/pl unknown
- 2016-07-27 CN CN201680025249.5A patent/CN107980040B/zh active Active
- 2016-07-27 JP JP2018504096A patent/JP6538266B2/ja active Active
- 2016-07-27 HR HRP20200280TT patent/HRP20200280T1/hr unknown
- 2016-07-27 AU AU2016299486A patent/AU2016299486B2/en active Active
- 2016-07-27 ES ES16830838T patent/ES2774510T3/es active Active
-
2017
- 2017-10-24 PH PH12017501939A patent/PH12017501939A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070293530A1 (en) | 2006-06-14 | 2007-12-20 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| WO2010123933A1 (en) | 2009-04-20 | 2010-10-28 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| US20120289495A1 (en) | 2010-01-13 | 2012-11-15 | Tempero Pharmaceuticals Inc. | Compounds and methods |
| WO2012013716A1 (en) | 2010-07-29 | 2012-02-02 | Novartis Ag | Bicyclic acetyl-coa carboxylase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| Bioorg Med Chem Lett., 2013.12., Vol.1, No.23, pp 6447-6454 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101799005B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| KR101799009B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| US10538498B2 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| AU2016303891A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| CN115210233B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物 | |
| CN115151542B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物 | |
| CN115427406B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物 | |
| CA3174319C (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| RU2810081C1 (ru) | Производные 1,3,4-оксадиазола в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция | |
| RU2822624C1 (ru) | Производные 1,3,4-оксадиазола в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция | |
| HK40074260A (en) | 1,3,4 oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| BR112018001716B1 (pt) | Composto de derivado de 1,3,4-oxadiazol amida como inibidor de histona desacetilase 6 e composição farmacêutica contendo o mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20160727 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170519 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20171102 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20171113 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20171113 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20200925 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210927 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220920 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230921 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240919 Start annual number: 8 End annual number: 8 |